Your browser is no longer supported. Please, upgrade your browser.
Gamida Cell Ltd.
Index- P/E- EPS (ttm)-1.17 Insider Own31.84% Shs Outstand49.47M Perf Week-11.32%
Market Cap497.34M Forward P/E- EPS next Y-1.25 Insider Trans0.00% Shs Float38.45M Perf Month-13.00%
Income-55.10M PEG- EPS next Q-0.34 Inst Own54.80% Short Float3.46% Perf Quarter22.24%
Sales- P/S- EPS this Y51.90% Inst Trans61.40% Short Ratio1.00 Perf Half Y98.56%
Book/sh1.22 P/B6.80 EPS next Y5.30% ROA-65.30% Target Price- Perf Year85.68%
Cash/sh1.22 P/C6.78 EPS next 5Y- ROE-112.80% 52W Range2.60 - 15.00 Perf YTD-1.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.67% Beta-
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low219.23% ATR1.00
Employees79 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)39.58 Volatility10.17% 10.07%
OptionableYes Debt/Eq0.00 EPS Q/Q23.40% Profit Margin- Rel Volume0.59 Prev Close8.43
ShortableYes LT Debt/Eq0.00 EarningsMar 09 BMO Payout- Avg Volume1.32M Price8.30
Recom1.90 SMA20-19.36% SMA50-11.74% SMA20032.40% Volume791,649 Change-1.54%
Jul-01-20Initiated Evercore ISI Outperform
May-26-20Initiated Piper Sandler Overweight $13
Apr-27-20Initiated H.C. Wainwright Buy $15
Nov-26-18Initiated Needham Buy $23
Nov-21-18Initiated Oppenheimer Outperform $15
Nov-20-18Initiated RBC Capital Mkts Outperform $20
Mar-03-21 07:00AM  
Mar-02-21 07:00AM  
Mar-01-21 07:00AM  
Feb-17-21 06:50AM  
Feb-16-21 07:00AM  
Feb-14-21 03:02AM  
Feb-10-21 02:44PM  
Feb-09-21 04:45PM  
Feb-01-21 02:46AM  
Jan-11-21 03:00PM  
Jan-05-21 04:01PM  
Dec-21-20 04:30PM  
Dec-18-20 08:00AM  
Dec-17-20 09:43AM  
Dec-16-20 09:03PM  
Dec-14-20 07:00AM  
Dec-10-20 08:17PM  
Dec-09-20 07:00AM  
Dec-07-20 03:33PM  
Dec-05-20 10:30AM  
Dec-02-20 08:01AM  
Nov-24-20 08:01AM  
Nov-16-20 04:17AM  
Nov-10-20 08:01AM  
Nov-04-20 10:30AM  
Nov-02-20 08:01AM  
Oct-13-20 08:01AM  
Oct-09-20 08:32AM  
Oct-07-20 10:14AM  
Oct-06-20 08:24AM  
Sep-10-20 09:01AM  
Sep-08-20 08:01AM  
Sep-03-20 08:01AM  
Aug-18-20 03:29PM  
Aug-17-20 08:00AM  
Aug-11-20 08:42AM  
Aug-04-20 08:31AM  
Jul-23-20 11:09AM  
Jul-21-20 08:01AM  
Jul-20-20 11:30AM  
Jul-07-20 08:30AM  
Jun-25-20 08:58AM  
Jun-19-20 12:00PM  
Jun-12-20 08:31AM  
Jun-10-20 04:34PM  
May-28-20 10:54AM  
May-26-20 09:01AM  
May-22-20 10:58AM  
May-21-20 09:22AM  
May-19-20 06:53PM  
May-18-20 10:40PM  
May-17-20 09:02AM  
May-13-20 10:12AM  
May-12-20 05:00AM  
Mar-02-20 09:23AM  
Feb-25-20 07:31AM  
Feb-19-20 08:01AM  
Jan-13-20 08:01AM  
Jan-02-20 08:01AM  
Dec-20-19 10:18AM  
Dec-10-19 07:56AM  
Dec-09-19 02:45PM  
Nov-21-19 08:01AM  
Nov-19-19 10:54AM  
Nov-13-19 04:01PM  
Nov-06-19 09:01AM  
Nov-05-19 08:31AM  
Oct-11-19 06:32PM  
Sep-11-19 08:00AM  
Aug-21-19 03:39PM  
Aug-19-19 08:12AM  
Aug-06-19 08:00AM  
Jul-23-19 08:01AM  
Jul-08-19 11:45AM  
Jun-26-19 09:30PM  
Jun-25-19 08:30AM  
Jun-24-19 04:12PM  
Jun-19-19 01:00AM  
Jun-05-19 08:35AM  
May-31-19 08:31AM  
May-29-19 08:31AM  
May-09-19 08:31AM  
May-07-19 04:23PM  
Apr-30-19 08:31AM  
Apr-22-19 08:31AM  
Apr-05-19 08:01AM  
Mar-21-19 08:29AM  
Mar-19-19 09:13AM  
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.